Vaxcyte
Stock Forecast, Prediction & Price Target
Vaxcyte (PCVX) stock Price Target by analysts
$148
Potential upside: 366.43%
Vaxcyte price prediction
What is Vaxcyte stock analysts` prediction?
Vaxcyte stock forecast: Based on 3 Wall Street analysts` predicted price targets for Vaxcyte in the last 3 months, the avarage price target is $148, with a high forecast of $NaN. The average price target represents a 366.43% change from the last price of $31.73.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Vaxcyte stock Price Target by analysts
Full breakdown of analysts given Vaxcyte price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Roger Song Jefferies | 0% 0/2 | 10 months ago | $146 360.13% upside | $106.74 | StreetInsider | Previous targets (1) |
David Risinger Leerink Partners | 0% 0/2 | 10 months ago | $135 325.46% upside | $106.74 | StreetInsider | Previous targets (1) |
Salim Syed Mizuho Securities | 0% 0/2 | 12 months ago | $163 413.70% upside | $115.28 | TheFly | Previous targets (1) |
Jason Gerberry Bank of America Securities | 0% 0/1 | about 1 year ago | $140 341.22% upside | $110.15 | TheFly | Previous targets (0) |
Salim Syed Mizuho Securities | 0% 0/2 | about 1 year ago | $113 256.12% upside | $111.09 | StreetInsider | Previous targets (1) |
Roger Song Jefferies | 0% 0/2 | about 1 year ago | $129 306.55% upside | $111.13 | StreetInsider | Previous targets (1) |
David Risinger Leerink Partners | 0% 0/2 | about 1 year ago | $153 382.19% upside | $112.04 | TheFly | Previous targets (1) |
Tom Shrader BTIG | 0% 0/2 | about 1 year ago | $160 404.25% upside | $110.15 | StreetInsider | Previous targets (1) |
Tom Shrader BTIG | 0% 0/2 | about 1 year ago | $98 208.85% upside | $70.52 | StreetInsider | Previous targets (1) |
Unknown Needham | N/A | over 2 years ago | $58 82.79% upside | $47.95 | Benzinga | N/A |
Unknown Leerink Partners | N/A | over 2 years ago | $60 89.09% upside | $45.48 | Benzinga | N/A |
Unknown Guggenheim | N/A | over 2 years ago | $66 108.00% upside | $45.72 | Benzinga | N/A |
Unknown BTIG | N/A | almost 3 years ago | $69 117.45% upside | $43.35 | Benzinga | N/A |
Vaxcyte Financial Estimates
Vaxcyte Revenue Estimates
Vaxcyte EBITDA Estimates
Vaxcyte Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $21.42M Low: $21.42M High: $21.42M avg. 0% | Avg: $92.76M Low: $92.76M High: $92.76M avg. 332.88% | Avg: $340.02M Low: $340.02M High: $340.02M avg. 266.56% |
Net Income
% change YoY
| $-100.08M N/A | $-239.64M -139.43% | $-402.26M -67.86% | Avg: $-506.68M Low: $-461.49M High: $-321.59M avg. -25.95% | Avg: $-540.14M Low: $-522.70M High: $-276.89M avg. -6.60% | Avg: $-392.51M Low: $-392.51M High: $-392.51M avg. 27.33% | Avg: $-262.08M Low: $-262.08M High: $-262.08M avg. 33.23% |
EBITDA
% change YoY
| $-98.28M N/A | $-189.77M -93.09% | $-464.88M -144.96% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$1.93 N/A | -$3.69 -91.19% | -$4.14 -12.19% | Avg: -$4.34 Low: -$4.75 High: -$3.31 avg. -4.85% | Avg: -$4.42 Low: -$5.38 High: -$2.85 avg. -1.91% | Avg: -$4.04 Low: -$4.04 High: -$4.04 avg. 8.68% | Avg: -$2.7 Low: -$2.7 High: -$2.7 avg. 33.23% |
Operating Expenses
% change YoY
| $102.08M N/A | $207.33M 103.09% | $468.04M 125.74% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Vaxcyte stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 7.00% in 2025-2028.
We have gathered data from 7 analysts. Their low estimate is -461.49M, average is -506.68M and high is -321.59M.
What is Vaxcyte stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 149.86% in 2025-2028.
We have gathered data from 8 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is Vaxcyte stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 8.78% in 2025-2028.
We have gathered data from 7 analysts. Their low earnings per share estimate is -$4.75, average is -$4.34 and high is $-3.31.
What is the best performing analyst?
In the last twelve months 3 analysts have been covering Vaxcyte stock. The most successful analyst is Roger Song.